Research Strand Drug Discovery and Design
Structure-based drug discovery and design
Leicester has traditionally had considerable strength in utilising structural biology to enhance the drug discovery process. This is reflected by a long-term partnership with UCB and LifeArc (formerly MRC-Technology) which has led to considerable Impact in previous REF exercises (Carr). More recently the engagement with drug discovery has been expanded to include a number of other researchers. This has resulted in a successful GSK DPAc award to develop molecules to target the BCL6 transcriptional repression complex (Schwabe); an award from ELF to generate novel molecules to modulate alternative splicing (Dominguez and Eperon); funding to develop molecularly imprinted polymers MIPS as “plastic antibodies” (Piletsky); our Chemical Biology lecturers are developing PROTACS to target large gene regulatory complexes (Hodgkinson) as well as metallopharmaceuticals (Suntharalingam).